alglucosidase alfa
Selected indexed studies
- Alglucosidase Alfa. (, 2006) [PMID:30000880]
- Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. (Lancet Neurol, 2021) [PMID:34800399]
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. (Lancet Neurol, 2021) [PMID:34800400]
_Worker-drafted node — pending editorial review._
Connections
alglucosidase alfa is a side effect of
Sources
- Alglucosidase Alfa. (2006) pubmed
- Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. (2021) pubmed
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. (2021) pubmed
- Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial. (2024) pubmed
- Pompe's disease. (2008) pubmed
- Pompe disease: Unmet needs and emerging therapies. (2024) pubmed
- Efficacy of transitioning from alglucosidase alfa to avalglucosidase alfa in infantile-onset Pompe disease: A single-center cohort analysis. (2025) pubmed
- Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature. (2020) pubmed
- Greater Efficacy of Avalglucosidase vs Alglucosidase Alfa in Adult Pompe Disease? The Jury Is Still Out. (2022) pubmed
- Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study. (2024) pubmed